Clinical Orthopaedics and Related Research®

, Volume 471, Issue 1, pp 231–237

Do Fresh Osteochondral Allografts Successfully Treat Femoral Condyle Lesions?

  • Yadin D. Levy
  • Simon Görtz
  • Pamela A. Pulido
  • Julie C. McCauley
  • William D. Bugbee
Symposium: Papers Presented at the Annual Meetings of the Knee Society

DOI: 10.1007/s11999-012-2556-4

Cite this article as:
Levy, Y.D., Görtz, S., Pulido, P.A. et al. Clin Orthop Relat Res (2013) 471: 231. doi:10.1007/s11999-012-2556-4



Fresh osteochondral allograft transplantation is an increasingly common treatment option for chondral and osteochondral lesions in the knee, but the long-term outcome is unknown.


We determined (1) pain and function, (2) frequency and types of reoperations, (3) survivorship at a median of 13.5 years, and (4) predictors of osteochondral allograft failure in the distal femur.


We evaluated 122 patients (129 knees) who underwent osteochondral allograft transplantation of the femoral condyle. Mean age was 33 years and 53% were male. Clinical evaluation included the modified Merle d’Aubigné-Postel (18-point), IKDC, and Knee Society function (KS-F) scores. We defined graft failure as revision osteochondral allografting or conversion to arthroplasty. We determined whether patient characteristics or attributes of the graft influenced failure. Minimum followup was 2.4 years (median, 13.5 years); 91% had more than 10 years of followup.


Mean modified Merle d’Aubigné-Postel score improved from 12.1 to 16, mean IKDC pain score from 7.0 to 3.8, mean IKDC function score from 3.4 to 7.2, and mean KS-F score from 65.6 to 82.5. Sixty-one knees (47%) underwent reoperations. Thirty-one knees (24%) failed at a mean of 7.2 years. Survivorship was 82% at 10 years, 74% at 15 years, and 66% at 20 years. Age of more than 30 years at time of surgery and having two or more previous surgeries for the operated knee were associated with allograft failure.


Followup of femoral condyle osteochondral allografting demonstrated durable improvement in pain and function, with graft survivorship of 82% at 10 years.

Level of Evidence

Level IV, therapeutic study. See the Instructions for Authors for a complete description of levels of evidence.

Copyright information

© The Association of Bone and Joint Surgeons® 2012

Authors and Affiliations

  • Yadin D. Levy
    • 1
    • 2
  • Simon Görtz
    • 3
  • Pamela A. Pulido
    • 1
  • Julie C. McCauley
    • 1
  • William D. Bugbee
    • 4
  1. 1.Shiley Center for Orthopaedic Research & Education at Scripps ClinicCAUSA
  2. 2.Department of Molecular and Experimental MedicineScripps Research InstituteCAUSA
  3. 3.Department of Orthopaedic SurgeryUniversity of California, San DiegoCAUSA
  4. 4.Division of Orthopaedic SurgeryScripps ClinicCAUSA

Personalised recommendations